How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

ABSTRACT: The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation.

The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.

Caracterização clínica e avaliação de sobrevida de uma coorte de pacientes com linfoma folicular diagnosticados eacompanhados no Instituto Nacional de Câncer / [Clinical characterization and survival assessment of a cohort of patients with follicular lymphoma diagnosed and followed up at the National Cancer Institute]

O linfoma folicular (LF) representa 25,0-30,0% dos linfomas em adultos, como neoplasia maligna de evolução indolente, sobrevida longa, resposta inicial ao tratamento seguida de recidivas. O evento crucial na história natural do LF é a transformação histológica para doença mais agressiva, associada a altas taxas de morbidade e mortalidade. O objetivo principal deste estudo foi descrever as características clínicas e avaliar o desfecho de pacientes portadores de LF diagnosticados, tratados e acompanhados no INCA entre 1996 a 2008. Foram analisados e validados três índices prognósticos internacionais conhecidos (IPI, ILI, FLIPI) na definição de grupos de riscos nesta série de pacientes, bem como testadas 2 simulações exploratórias (nomeadas ILI-B e FLIPI-B). Foram analisadas as informações clínicas retrospectivas, compiladas na base de dados dataLINFO de 136 pacientes com diagnóstico confirmado de LF (53,6% grau I, 32,4% grau II e 14,0% grau III). Na coorte estudada a maioria dos pacientes se apresentou com doença avançada ao diagnóstico (73,5%) porém assintomáticos (83,5% com PS<2). Durante o tempo de acompanhamento (6,5 anos) a transformação para linfoma de alto grau foi observada em 15 pacientes (11,0%)...

Follicular lymphoma (FL) represents 25,0-30,0% of lymphomas in adults, as an indolent malignancy, long survival, initial treatment response followed by relapse. The crucial event in the natural history of the LF is the histologic transformation to a more aggressive disease, associated with high morbidity and mortality. The main objective of this study was to describe and evaluate the clinical outcome of patients with LF diagnosed, treated and followed INCA in the period between 1996 to 2008. We reanalyzed and validated three known international prognostic (IPI, ILI, FLIPI) in the definition of risk groups in this series of patients, and tested two exploratory simulations (named ILI and FLIPI-B-B). We analyzed retrospective clinical information, compiled in the database dataLINFO of 136 patients with confirmed diagnosis of LF (53.6% grade I, 32.4% grade II and 14,0% grade III). In our cohort the majority of patients presented with advanced disease at diagnosis (73.5%) to asymptomatic (83.5% with PS <2). During the follow-up (6.5 years) the transformation to high grade lymphoma was observed in 15 patients (11,0%)...